GlassScriptPhysician profile
Heather D Rupe
NPI 1548252984
$8,276.13
in general payments reported to CMS, 2019-2025
30 companies · $843 in 2025
The $843 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $303 · 2021: $4,618 · 2022: $739 · 2023: $754 · 2024: $432 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,929 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,929.08 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,129.01 | 2021-2022 | |
| Abbvie INC. | $717.78 | 2019-2025 | Lo Loestrin Fe |
| Astellas Pharma US INC | $564.40 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $395.16 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $372.93 | 2021-2025 | |
| Coopersurgical, INC. | $238.05 | 2019-2025 | Endosee, Paragard T 380a, Mara Console |
| Amgen INC. | $222.80 | 2019-2021 | |
| Biogen, INC. | $189.18 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $175.44 | 2019-2025 | Slynd |
| Channel Medsystems, INC. | $141.06 | 2022-2024 | |
| Millicent US INC | $138.39 | 2022-2025 | Intrarosa, Femring, Femlyv |
| Agile Therapeutics, INC. | $117.07 | 2021-2022 | |
| Pfizer INC. | $115.37 | 2021-2025 | |
| Organon LLC | $106.37 | 2022-2024 | |
| Mylan Pharmaceuticals INC. | $94.96 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $68.83 | 2019-2021 | |
| Hologic Sales and Service, LLC | $68.53 | 2019-2023 | Myosure Tissue Removal Device, Omni Hysteroscope |
| Evofem Biosciences, INC. | $66.67 | 2021-2022 | |
| Exact Sciences Corporation | $57.59 | 2023-2024 | Cologuard Collection Kit |
| Minerva Surgical, INC | $42.77 | 2025 | |
| Merck Sharp & Dohme LLC | $40.21 | 2019-2020 | |
| Duchesnay USA Incorporated | $31.60 | 2019 | |
| Lupin INC. | $28.34 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $27.80 | 2025 | Myfembree |
| Meditrina | $27.29 | 2023-2025 | |
| Allergan, INC. | $25.29 | 2019-2020 | |
| Medtronic, INC. | $24.01 | 2022 | |
| Gynesonics, INC. | $22.54 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Therapeuticsmd, INC. | $14.25 | 2020 | |
| Olympus America INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Rupe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.